- Home
- LSF vs APLT Comparison
LSF vs APLT Comparison
Compare LSF & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- APLT
- Stock Information
- Founded
- LSF 2015
- APLT 2016
- Country
- LSF United States
- APLT United States
- Employees
- LSF N/A
- APLT N/A
- Industry
- LSF Packaged Foods
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- APLT Health Care
- Exchange
- LSF Nasdaq
- APLT Nasdaq
- Market Cap
- LSF 71.7M
- APLT 80.3M
- IPO Year
- LSF 2020
- APLT 2019
- Fundamental
- Price
- LSF $7.27
- APLT $0.53
- Analyst Decision
- LSF Strong Buy
- APLT Buy
- Analyst Count
- LSF 2
- APLT 7
- Target Price
- LSF $7.75
- APLT $6.10
- AVG Volume (30 Days)
- LSF 59.9K
- APLT 3.0M
- Earning Date
- LSF 02-26-2025
- APLT 03-05-2025
- Dividend Yield
- LSF N/A
- APLT N/A
- EPS Growth
- LSF N/A
- APLT N/A
- EPS
- LSF N/A
- APLT N/A
- Revenue
- LSF $40,896,326.00
- APLT N/A
- Revenue This Year
- LSF $27.95
- APLT N/A
- Revenue Next Year
- LSF $21.07
- APLT $2,622.90
- P/E Ratio
- LSF N/A
- APLT N/A
- Revenue Growth
- LSF 20.33
- APLT N/A
- 52 Week Low
- LSF $0.71
- APLT $0.53
- 52 Week High
- LSF $10.90
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- LSF 46.79
- APLT 29.75
- Support Level
- LSF $6.89
- APLT $0.54
- Resistance Level
- LSF $7.72
- APLT $0.70
- Average True Range (ATR)
- LSF 0.47
- APLT 0.06
- MACD
- LSF -0.01
- APLT 0.06
- Stochastic Oscillator
- LSF 32.97
- APLT 0.00
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.